Skip to main content

Advertisement

Log in

Comparing the Recurrence of Vulvovaginal Candidiasis in Patients Undergoing Prophylactic Treatment with Probiotic and Placebo During the 6 Months

  • Published:
Probiotics and Antimicrobial Proteins Aims and scope Submit manuscript

Abstract

This is a randomized, double-blind, clinical/comparative trial study, involving the recurrence of vaginal candidiasis (VVC) after initial treatment with oral fluconazole in patients undergoing prophylactic management with a probiotic and placebo for 6 months. Fifty-nine VVC patients who were diagnosed based on their history, physical examination, and culture of vaginal discharge were initially treated by a single dose of 150 mg fluconazole. According to the table of random numbers, the sample was divided into two groups. The patients from one group took probiotics, while those from the other group took a placebo, with all of them being continuously monitored for 6 months. The patients complaining of vaginal candidiasis symptoms, such as burning, pruritus, and a vaginal (curd-like) discharge, were examined and the discharge was cultured for candida. The positive cultures were considered to be recurring for the patients in each group. Thirty-one cases from the placebo group and 28 cases from the probiotic group were carefully observed. In total, the 6-month recurrence in the control group was eleven (35.5 %) and in the research group was two (7.2 %). The results from Fisher’s exact test for the value p = 0.01 and OR 0.14 95 % CI (0.028–0.7) showed significant recurrence in the placebo group. The findings demonstrated that taking probiotics withazole antifungal drugs could be highly effective in treating VVC, resulting in a lower recurrence rate as well.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Geiger AM, Foxman B, Gillespie BW (1995) The epidemiology of vulvovaginal candidiasis among university students. Am J Public Health 85:1146. doi:10.2105/AJPH.85.8_Pt_1.1146

    Article  CAS  Google Scholar 

  2. Geiger AM, Foxman B (1996) Risk factors for vulvovaginal candidiasis: a case-control study among university students. Epidemiology 7:182. doi:10.1097/00001648-199603000-00013

    Article  CAS  Google Scholar 

  3. Hurley R, De Louvois J (1979) Candida vaginitis. Postgrad Med J 55:645. doi:10.1097/00001648-199603000-00013

    Article  CAS  Google Scholar 

  4. Sobel JD (1985) Epidemiology and pathogenesis of recurrent vulvovaginal candidiasis. Am J Obstet Gynecol 152:924. doi:10.1016/s0002-9378(85)80003-x

    Article  CAS  Google Scholar 

  5. Houang ET, Chappatte O, Byrne D et al (1990) Fluconazole levels in plasma and vaginal secretions of patients after a 150-milligram single oral dose and rate of eradication of infection in vaginal candidiasis. Antimicrob Agents Chemother 34:909. doi:10.1128/aac.34.5.909

    Article  CAS  Google Scholar 

  6. Iannitti T, Palmieri B (2010) Therapeutical use of probiotic formulations in clinical practice. Clin Nutr 29:701–725. doi:10.1016/j.clnu.2010.05.004

    Article  CAS  Google Scholar 

  7. Sobel JD et al (2004) Maintenance fluconazole therapy for recurrent vulvovaginalcandidiasis. N Engl J Med 351:876–883. doi:10.1056/nejmoa033114

    Article  CAS  Google Scholar 

  8. Reid G et al (2003) Oral use of lactobacillus rhamnosus GR-1 and lactobacillus fermentum RC-14 significantly alters vaginal flora. FEMS Immunol Med Microbiol 35:131–134. doi:10.1016/s0928-8244(02)00465-0

    Article  CAS  Google Scholar 

  9. Ramezanzade F (2001) Survey and compare with treatment and recurrence of VVC. Hakim J 103–108

  10. Mendeling w et al (2004) Copering efficacy and tolerability of typical combination therapy with clotrimazol and single dose fluconazole in vulvovaginalmycoses. Mycoses 47:136–142. doi:10.1111/j.1439-0507.2004.00970.x

    Article  Google Scholar 

  11. Ehrstrom S, Daroczy K, Rylander E, Samuelsson C, Johannesson U et al (2010) Lactic acid bacteria colonization and clinical outcome after probiotic supplementation in conventionally treated bacterial vaginosis and vulvovaginal candidiasis. Microbes Infect 12:691–699. doi:10.1016/j.micinf.04.010

    Article  Google Scholar 

  12. Martinez RCR et al (2009) Improved treatment of vulvovaginitis candidiasis with fluconazole plus probiotic lactobacillus rhamnosus GR-1 and lactobacillus reuteri RC-14. Soc Appl Microbiol 48:269–274. doi:10.1111/j.1472-765x.2008.02477.x

    Article  CAS  Google Scholar 

  13. Kingsley C et al (2009) Oral use of probiotic as an adjunctive theropy to fluconazole in the treatment of yeast vaginitis. Microbial Ecol Health Dis 21:72–77. doi:10.1080/08910600902907475

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Fahimeh Nokhostin.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Davar, R., Nokhostin, F., Eftekhar, M. et al. Comparing the Recurrence of Vulvovaginal Candidiasis in Patients Undergoing Prophylactic Treatment with Probiotic and Placebo During the 6 Months. Probiotics & Antimicro. Prot. 8, 130–133 (2016). https://doi.org/10.1007/s12602-016-9218-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12602-016-9218-x

Keywords

Navigation